Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy participants ≥6 months and ≤45 years of age at enrolment~2. Participants/Parents/Legally Authorized Representative(LAR) willing to give written informed consent/assent to participate in the trial~3. Participants/Parents/LAR willing to follow the study procedures of the study and available for the entire duration of the study~4. Participants who are healthy as determined by medical history, with no clinically significant abnormalities in clinical examination and laboratory tests~5. Female participants must have a negative serum (at Screening) and negative urinary (at Day 1) pregnancy test and agree to use 2 methods of contraception from dosing until 90 days after vaccination.~Exclusion Criteria:~1. Participants/Parents/LAR unwilling to give his/her consent/assent to participate in the trial~2. Participants concomitantly enrolled or scheduled to be enrolled in another trial~3. Children and infants with a congenital abnormality~4. Known history of immune function disorders including immunodeficiency disease, or chronic use of systemic steroids, cytotoxic or other immunosuppressive drugs~5. Pregnant, lactating women or women of childbearing age not using a reliable method of contraception~6. History of uncontrolled coagulopathy or blood disorders~7. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives~8. History of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Vi-CRM197, Batch #1) (Type: EXPERIMENTAL): Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.
- Arm A (Vi-CRM197, Batch #2) (Type: EXPERIMENTAL): Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.
- Arm A (Vi-CRM197, Batch #3) (Type: EXPERIMENTAL): Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.
- Arm D (Typbar-TCV) (Type: ACTIVE_COMPARATOR): Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).